Loading...
•
Dec 31, 2020
Capricor Q4 2020 Earnings Report
Reported a net loss for the fourth quarter and full year 2020, advanced in engineered exosome platform technology, and continued progress in clinical-stage cell therapy programs.
Key Takeaways
Capricor Therapeutics reported a net loss of $4.2 million, or $0.21 per share, for the fourth quarter of 2020, compared to a net loss of $1.5 million, or $0.34 per share, for the fourth quarter of 2019. As of December 31, 2020, the Company’s cash, cash equivalents and marketable securities totaled approximately $32.7 million.
Net loss of approximately $4.2 million, or $0.21 per share, for the fourth quarter of 2020.
Appointment of Dr. Stephen Gould as executive consultant to guide the development of exosome platform.
Planning on moving SARS-CoV-2 vaccine into the clinic in 2021, subject to regulatory approval.
Discussions with FDA on pathway to approval for Duchenne Muscular Dystrophy.
Forward Guidance
Capricor expects that the cash, cash equivalents and marketable securities will be sufficient to cover expenses and capital requirements through at least the second quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...